J Neurol Neurosurg Psychiatry 96:870883
In addition to GLP-1 RA monoagonists (eg, semaglutide), dual incretin receptor agonists targeting GLP-1R and glucose-insulinotropic polypeptide receptors (GIP) (eg, tirzepatide) are now available, with anticipated approval of triple agonists (eg, retatrutide
fda.gov FDA 503A bulk drug substances list updates, April 2026 (12 peptides removed from Category 2 for evaluation)
Semaglutide has a safety profile, clinical backing, and FDA-approval
State rules can add another layer, so the buyer is responsible for checking local law
Some commentators have compared the impact that GLP-1 drugs have had on society, particularly in relation to the treatment of obesity, to the revolution brought about by the the arrival of the contraceptive pill in the 1960s